Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

443

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Investigators choice of SoC
DRUG: AAA817
DRUG: AAA817
DRUG: AAA817

Sponsor

Novartis Pharmaceuticals